Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation
Clinical trial NCT04500717 · UNKNOWN
Trial details
- NCT number
- NCT04500717
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-01
- Primary completion
- 2022-10-01
- Enrollment
- 460
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.